Disease Markers

Group Leads: P Kehoe, PJ Visser

  • Genetics
  • Biomarkers
  • Imaging

The objectives of this group are:

  • To identify contemporary and strategic opportunities presented by the rapidly evolving basic research technologies and imaging with a view to researching new approaches and tools for improved diagnosis of dementia and outcome measurement in treatment and clinical trials
  • To develop strategies to manage the undertaking of molecular epidemiological studies on Alzheimer’s disease and related disorders on a European scale, including the development of mechanisms towards:    - shared DNA banking;
       - uniform biomaterial handling and preparation;
       - uniform handling of probes;
       - harmonisation of phenotype information and criteria including methods towards the normalisation of imaging data gained under imaging platforms of different specifications;
       - harmonisation of ethical principles.
  • To design, gain funding for and conduct multidisciplinary studies taking advantage of these unique resources which can be used on both more or less common forms of dementia.

Ongoing projects:

  • The "EADC PET 2.0" project.
  • The "EADC PET" project.
  • The "EADC-ADNI hippocampal harmonization" project. Main site.
  • The EADC specialists' opinions on diagnostic biomarkers. The aim was to collect information on when and how biomarkers are currently used in EADC memory clinics for the diagnosis of prodromal AD. An online questionnaire survey was conducted among EADC centres to investigate the views on aspects of decision making in clinical scenarios involving early diagnosis of people with cognitive impairment. Responses to this survey are hoped to form the basis of a position paper to be drafted by the Disease Markers Group - on behalf of the EADC.
  • neuGRID: an e-Infrastructure for high-throughput image analysis. Main site.

Closed projects: